This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- PEGylated Recombinant Factor VIII
- DrugBank Accession Number
- DB16093
- Background
PEGylated Recombinant Factor VIII is under investigation in clinical trial NCT02585960 (BAX 855 Pk-guided Dosing).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Adynovate
- Adynovi
- Antihemophilic factor (recombinant), pegylated (20 kda)
- Antihemophilic factor (recombinant), pegylated (mw 20000)
- Antihemophilic factor, pegylated (mw 20000) human sequence recombinant
- PEGylated Recombinant Factor VIII
- Pegylated rfviii
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5X3GF74R79
- CAS number
- 1417412-83-9
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Not Yet Recruiting Treatment Hemophilia A 1 4 Recruiting Treatment Factor VIII (FVIII) / Hemophilia A 1 3 Active Not Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / Hemophilia A 1 3 Completed Prevention Hemophilia A 2 3 Completed Treatment Hemophilia A 2 3 Not Yet Recruiting Treatment Hemophilia A 1 2, 3 Completed Prevention Hemophilia A 1 1 Completed Treatment Hemophilia A 1 Not Available Completed Not Available Hemophilia 1 Not Available Completed Not Available Hemophilia A 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 15, 2020 18:05 / Updated at December 20, 2020 03:36